

n.c.a. Lutetium-177

SMARTER CANCER THERAPY,
NOW AVAILABLE



Next Generation Cancer Therapy

SHINE is dedicated to facilitating the worldwide supply of n.c.a. lutetium-177 with enhanced scalability and security of supply.

Key Advantages

U.S.-based production and logistics

Expanded U.S. production coming online in late 2023

Exceeds European Pharmacopeia standards

U.S.-based proprietary ytterbium-176 enrichment

Produced in accordance with current Good Manufacturing Practice

Drug Master File submitted to U.S. Food and Drug Administration (FDA)

Commercial facility in Europe planned for 2025

The Future of Cancer Treatment is Now

To learn more, call (608) 530-5653 or email orders@shinefusion.com

Vertically Integrated Production for Readily Available Product

We are working to become the first vertically integrated manufacturer of n.c.a. lutetium-177 in the world. By establishing a proprietary U.S.-based supply of Yb-176, we have reduced market dependency for sole-sourced critical raw material.



n.c.a. Lu-177 Product Specifications

Packaging Options	<ul style="list-style-type: none"> • 10 mL flat bottom glass vial • 2 mL flat bottom glass vial • 2mL conical glass vial
Radiolabeling Yield	≥ 99%
Chemical Form	n.c.a. LuCl ₃ in 0.04M HCl solution
Specific Activity	ART > 3,000 GBq/mg
Radionuclidic Purity	> 99.9% ¹⁷⁷ Lu
Radiochemical Purity	> 99% as ¹⁷⁷ LuCl ₃
Shelf Life	10 Days



The Future of Cancer Treatment is Now

To learn more, call (608) 530-5653 or email orders@shinefusion.com